NidlegyTMwas found to be well-tolerated and 149 out of the anticipated 214 patients have been safely treated.
Data Safety Monitoring Board recommends to continue the study as planned.
News & Events
Philogen announces the completion of a second interim analysis of its phase III clinical program with NidlegyTM for the treatment of melanoma
Last News & Events
No Results Found
The posts you requested could not be found. Try changing your module settings or create some new posts.